CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in geriatric population and rise in awareness regarding fibrin sealants
3.4.1.2. Growth in the prevalence of chronic diseases and rise in the number of surgical procedures conducted globally
3.4.2. Restraints
3.4.2.1. High cost of fibrin sealants and availability of alternate products
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging countries
CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS
4.1. Overview
4.1.1. Market size and forecast
4.2. Liquid
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Liquid Fibrin Sealants Market by Liquid Type
4.3. Patch
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Powder
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. General Surgery
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiovascular Surgery
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Wound Management
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Orthopedic Surgery
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Urological Surgeries
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Ophthalmic Surgeries
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Others
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ambulatory Surgical Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Clinics
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Dosage Forms
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Dosage Forms
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Dosage Forms
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Dosage Forms
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Dosage Forms
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Dosage Forms
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Dosage Forms
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Dosage Forms
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Dosage Forms
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Dosage Forms
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Dosage Forms
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Dosage Forms
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Dosage Forms
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Dosage Forms
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Dosage Forms
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Dosage Forms
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Dosage Forms
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Dosage Forms
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Dosage Forms
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Dosage Forms
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa
7.5.5.2.1. Market size and forecast, by Dosage Forms
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Saudi Arabia
7.5.5.3.1. Market size and forecast, by Dosage Forms
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Dosage Forms
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Baxter International Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Becton, Dickinson and Company
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Corza Medical
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Key strategic moves and developments
9.4. CSL Behring
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Grifols, S.A.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Hemarus Therapeutics Ltd.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Johnson and Johnson
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Nordson Corporation (Nordson Medical)
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Shanghai Raas Blood Products Co. Ltd
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Vivostat A/S
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
| ※参考情報 フィブリンシーラントは、手術や外傷治療において出血を抑えるために用いられる生物学的接着剤の一種です。フィブリンシーラントは、フィブリンというタンパク質を基にしており、血液が凝固する過程で重要な役割を果たします。出血を止めるための物質として、特に外科手術や創傷市場で広く利用されています。 フィブリンシーラントの主要な種類には、自己血由来のものと製造されたものがあります。自己血由来のフィブリンシーラントは、患者自身の血液から作られ、血液成分を抽出し、フィブリンを生成して用います。一方、製造されたフィブリンシーラントは、動物由来またはヒト由来の血液を元にして作られ、商品化された形で提供されます。一般的には、ヒト由来の製品の方が免疫反応のリスクを低くするため、医療現場での利用が進んでいます。 フィブリンシーラントの用途は多岐にわたります。外科手術においては、出血のコントロール、創傷の閉合、組織の接着などに利用されます。特に、心臓や肝臓、整形外科手術において、その効果が顕著に見られます。また、フィブリンシーラントは、開腹手術や内視鏡手術などの侵襲的手術においても使用され、早期回復や合併症のリスクを軽減する手助けをします。 フィブリンシーラントの効果は、その構成成分に依存しています。フィブリンは、トロンビンとフィブリノーゲンの反応によって生成され、その際に生成されるフィブリンネットワークが出血を止める役割を果たします。このため、フィブリンシーラントは、迅速に血液凝固を促進し、現場での出血を速やかにコントロールすることができます。また、フィブリンシーラントには、組織再生を促す作用もあり、創傷の治癒をサポートする機能も持っています。 関連技術としては、フィブリンシーラントを効果的に使用するためのデリバリーシステムが挙げられます。これには、シーラントを正確に傷口に適用するためのシリンジやスプレー式のアプリケーターが含まれます。また、最近では、自動化されたデリバリーシステムが開発されており、これにより手術中のフィブリンシーラントの投与がより正確かつ迅速に行えるようになっています。 さらに、フィブリンシーラントはバイオマテリアル技術の一環とも言え、さまざまな素材と組み合わせて利用されるケースも増えています。例えば、生体適合性を持つポリマーと組み合わせることで、より強力な接着力を有する製品が開発されたり、薬剤を封入したフィブリンシーラントが開発され、感染予防や炎症抑制の効果を持つ製品も市場に登場しています。 フィブリンシーラントは、その生物学的特性から、外部からの刺激に対しても自然な反応を示すため、体内での安全性が高いとされています。しかしながら、何らかのアレルギー反応や感染症のリスクは完全には排除できないため、使用時には医療従事者による適切な評価と管理が求められます。 このように、フィブリンシーラントは、外科手術や創傷治療において非常に重要な役割を果たしており、その用途や関連技術が日々進化し続けています。医療の現場においてフィブリンシーラントを適切に利用することで、患者の治療効果を向上させることが期待されています。今後の研究や技術革新により、さらなる利用範囲の拡大や安全性の向上が期待される分野です。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
-gr.jpg)
